medwireNews

Researchers have validated a blood test involving B-cell receptor clones that could determine which healthy individuals at risk for rheumatoid arthritis are likely to develop the condition in the short term.

Study results presented at the EULAR 2018 meeting in Amsterdam, the Netherlands, indicate that improvements in joint and skin symptoms seen with risankizumab treatment are maintained for 24 weeks among patients with psoriatic arthritis.

Adding the additional target of no osteitis or bone marrow edema on magnetic resonance imaging to a conventional treat-to-target regimen does not improve the clinical or radiographic outcomes of rheumatoid arthritis patients in clinical remission, IMAGINE-RA study findings show.

The addition of once-daily baricitinib to standard background therapy could improve clinical outcomes in patients with systemic lupus erythematosus, phase II trial findings show.

Researchers have found an increased risk for self-harm in patients with ankylosing spondylitis.

Patients with advanced non-small-cell cancer with activating EGFR mutations derive a significant overall survival benefit from first-line treatment with dacomitinib relative to gefitinib, the ARCHER 1050 trial shows.